Season 2 (2021-2030)

Oncology - Small Molecules (70)

Modality Indication Targets Stage Company Project No. Detail
1 Global phase 2 studies of precision medicine based c.MET inhibitor ABN401
Small Molecules Solid tumor, NSCLC c.MET Phase 2 Abion Inc. RS-2023-00284103
2 Identification of small molecule PKMYT1 inhibitor candidates for development of advanced solid tumor treatment
Small Molecules Solid tumor PKMYT1 Candidate Voronoi Inc. RS-2023-00283890
3 Discovery of VRK1 inhibitor for precision medicine of advanced/ refractory solid cancer
Small Molecules Solid Tumor VRK1 Hit Korea Reserch Institute Of Chemical Technology(KRICT) RS-2023-00283832
4 Development of SIRT7 inhibitors for the treatment of unresectable hepatocellular carcinoma
Small Molecules Cancer SIRT7 Lead Korea Reserch Institute Of Chemical Technology(KRICT) RS-2023-00283539
5 A Study on the Development of First.in.class Myc Inhibitor Candidate for the Treatment of Solid Tumor and Hematologic Cancer
Small Molecules Cancer Myc Candidate Incurix Co., Ltd. RS-2023-00283511
6 Non.clinical development of C2.558, a SOS1 inhibitor, for the treatment of patients with KRAS mutant solid tumors
Small Molecules Solid tumor KRAS.SOS1 PPI Preclinical Cyrus Therapeutics Inc. RS-2023-00283208
7 Non.clinical development of CYRS1542, a GSPT1 Molecular Glue Degrader, for the treatment of patients with SCLC and AML
Small Molecules SCLC, AML GSPT1 Preclinical Cyrus Therapeutics Inc. RS-2023-00282972
8 Phase 1 clinical Study of ENPP1 inhibitory Immunotherapy TXN10128
Small Molecules Solid tumor ENPP1 Phase 1 Txinno Bioscience Inc. RS-2023-00282830
9 Development of an NMC Therapeutic Candidate Using a BRD4.NUT Degrader
Small Molecules NUT Midline Carcinoma BRD4.NUT Candidate Innocure Therapeutics Inc. RS-2023-00282701
10 Development of novel small molecule anticancer drugs targeting SMARCA2
Small Molecules NSCLC, Melanoma SMARCA2/4 Candidate Hyundai Pharm RS-2023-00259457
11 Development of third-generation antibody-drug conjugate linker technology capable of site-selectively conjugating payloads without antibody modification
Small Molecules Gastric/GEJ AbClickⓇPro Lead AbTis Co., Ltd. RS-2023-00259367
12 Preclinical development of a MET degrader as a novel NSCLC agent
Small Molecules NSCLC MET (a receptor tyrosine kinase) Preclinical InnoCure Therapeutics RS-2023-00259138
13 Development of small molecule targeting FoxM1 for the treatment of colorectal cancer
Small Molecules Solid Cancer FoxM1 Lead Korea Research Institute of Chemical Technology(KRICT) RS-2023-00258901
14
Small Molecules Solid Cancer TLS Lead D5 Therapeutics RS-2023-00258885
15 The generation of candidate for Relapsed and Refractory Acute Myeloid Leukemia to FLT3 inhibitors via direct STAT5/3 inhibition
Small Molecules Acute Myeloid Leukemia STAT3/5 Candidate JW C&C Research Laboratories RS-2023-00258859
16 Development of a new Topoisomerase I inhibitor based on a Kamtotesin derivative that can be used as an ADC payload
Small Molecules Solid Tumor Topoisomerase I Lead Pinotbio, Inc. RS-2023-00258783
17 Direct inhibitor of AR/AR.V7 DNA binding for castration.resistant prostate cancer
Small Molecules Castration.resistant prostate cancer Androgen receptor (AR) and AR.V7 Candidate Incurix RS-2023-00258594
18 Lead optimization and candidate selection of PD.L1 small molecule inhibitor for non.clinical study
Small Molecules Solid Cancer PD.1/PD.L1 Candidate Ilab RS-2023-00258167
19 Nonclinical development of AR degrader UBX.103335 for the treatment of metastatic castration.resistant prostate cancer
Small Molecules Castration.resistant prostate cancer Androgen receptor (AR) Preclinical Ubix Therapeutics RS-2023-00258142
20 Phase I Clinical Study of WM-S1-030 in patients with advanced or metastatic solid tumor
Small Molecules Colorectal cancer mutant RON Phase 1 Wellmarkerbio Co., Ltd. RS-2023-00219060
21 Pre-clinical development of SCB0020160, a Sirt6 agonist with a potent anti-cancer effect
Small Molecules pancreatic cancer SIRT6 Preclinical SCBIO RS-2023-00218894
22 Development of novel lead compounds inducing integrated stress response through HRI activation for the treatment of hematologic malignancies
Small Molecules polycythemia vera HRI Lead NexThera Co., Ltd. RS-2023-00218778
23 First-in-Class FLT3 Degrader Discovery Using PROTACs and Chemoproteomics
Small Molecules Acute myeloid leukemia, AML FLT3 Lead Yonsei University Industry-University Cooperation Foundation RS-2023-00218195
24 Developing Lead compound of AURKA Degrader for a potential anti-cancer therapy
Small Molecules Cancer AURKA Lead UPPthera, Inc. RS-2023-00217986
25 Discovery of pre-clinical candidates for inhibition of SOS1 for the treatment of KRAS mutated cancers
Small Molecules KRAS-mutated solid cancer(Pancreatic, Lung, Colon cancer) SOS1 Candidate Jeil Pharmaceutical RS-2023-00217674
26 Non-clinical studies of VRN101099, a brain permeable HER2 selective kinase inhibitor
Small Molecules Breast cancer, Colon cancer HER2 Preclinical VORONOI RS-2023-00217541
27 Development of next-generation allosteric EGFR inhibitor for non-small cell lung cancer treatment
Small Molecules NSCLC EGFR Candidate HK inno.N RS-2023-00217095
28 Pre-clinical development of anticancer candidate to treat small cell lungcancer (SCLC) through PROTAC-based PLK1 protein degradation
Small Molecules NSCLC PLK1 Preclinical UPPPTHERA RS-2022-00167113
29 Structure based drug discovery of FOXM1 inhibitor for malignant tumor therapy
Small Molecules Malignant tumor FOXM1 Hit Korea University College of Medicine RS-2022-00167112
30 A Phase 1b/2a Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of TU2218, an oral TGFβR Serine/Threonine Kinase Inhibitor, Administered in Combination with Pembrolizumab in Patients with Advanced Solid Tumors
Small Molecules Solid Tumor TGFβR1 Phase 1 Tium BIO RS-2022-00167091
31 Development of therapeutics for acute myeloid leukemia with CK1alpha selective molecular degrader
Small Molecules AML CK1α Candidate Pin Therapeutics RS-2022-00166852
32 Discovery of STING allosteric activator targeting non-T cell inflamed tumor
Small Molecules Solid Tumor STING Hit Korea Institute of Science and Technology RS-2022-00166522
33 Non-clinical Development of SREBP1 Degrader for the Cancer Stem Cell-targeted Treatment of Glioblastoma
Small Molecules Glioblastoma SCAP:SREBP1 Preclinical MEDIFIC RS-2022-00166323
34 Development of 19S RP UCHL5 inhibitors for the treatment of relapsed and refractory multiple myeloma
Small Molecules Multiple Myeloma 19S RP UCHL5 Lead Korea Research Institute of Bioscience and Biotechnology RS-2022-00166286
35 Discovery of novel PIP5K1a inhibitors as lead compounds for mCRPC therapy
Small Molecules Prostate cancer PIP5K1α Lead TSD Life Sciences RS-2022-00165973
36 Non-clinical study on the development of customized targeted anticancer agent for the treatment of advanced Hepatocellular Carcinoma
Small Molecules Liver cancer FLT3/VEGFR2/PDGFRb TK Preclinical Etnova Therapeutics RS-2022-00165725
37 Development of a novel HPK1/MLK3 dual inhibitor, an immuno-oncology agent for MLK3-specific solid tumors
Small Molecules Brain cancer, Lung cancer HPK1/MLK3 Lead MD Biolab RS-2022-00165566
38 Development of **** inhibitor for immuno-metabolic modulator
Small Molecules Colorectal cancer GCN2 Lead 1st Biotherapeutics, Inc RS-2022-00165544
39 Clinical Phase 1 Development of SKL27969, a Novel Brain Penetrating PRMT5 Inhibitor
Small Molecules Glioblastoma PRMT5 Phase 1 SK Biopharmaceuticals RS-2022-00165541
40 Discovery of novel TTK (MPS1) inhibitors for the TNBC treatment
Small Molecules TNBC TTK Lead Korea Research Institute of Chemical Technology HN22C0694
41 Anti-DX2 chemical drug to control KRAS-driven cancer
Small Molecules Colorectal cancer (KRAS mutation) KRAS Candidate Zymedi HN22C0682
42 An Oral, Selective, and Potent EGFR Mutant Protein Degrader for the Treatment of NSCLC
Small Molecules NSCLC(EGFR mutation) EGFR Preclinical J2H Biotech HN22C0670
43 Non-clinical study of VRN11, a CNS-penetrable inhibitor for EGFR
G719X, L861X, S768I/V as well as C797S mutation NSCLC patients
Small Molecules NSCLC(EGFR mutation) EGFR Preclinical Voronoi, Inc HN22C0663
44 Development of dual-functional hit/lead compounds targeting N3, a regulator of KRAS stability for the treatment of pancreatic cancer
Small Molecules Pancreatic cancer NDRG3 Hit Korea Research Institute of Bioscience and Biotech HN22C0638
45 Discovery of Translocator Protein Targeting Cancer Therapeutics as effective substances
Small Molecules Glioblastoma TSPO Hit Seoul National University HN22C0632
46 Preclinical study of DA-4505 for the treatment of cancer immunotherapy
Small Molecules Advanced Solid Tumor AhR Preclinical DONG-A ST HN22C0630
47 JW2286, a novel inhibitor directly targeting of STAT3, drug discovery for solid cancer including triple negative cancer
Small Molecules TNBC STAT3 Preclinical JW Pharmaceutical HN22C0583
48 Polo-like kinase 1(PLK1) degradation using the N-degron pathway in PROTACs and its application of developing to non-small cell lung cancer(NSCLC) target drug candidates
Small Molecules NSCLC PLK1 Candidate DANDI CURE HN22C0563
49 ENPP1 Inhibitor TXN10128
Small Molecules Colorectal cancer ENPP1 Preclinical TXINNO Bioscience Inc HN22C0531
50 Discovery and development of novel ULK1 inhibitor as a therapeutic drug for RAS-mutated cancers
Small Molecules Colorectal cancer, Lung cancer, Pancreatic cancer ULK1 Lead TXINNO Bioscience Inc HN22C0244
51 Development of first-in class MASTL-targeted drug in triple-negative breast cancer
Small Molecules Breast Cancer MASTL Lead Korea Institute of Radiological & Medical Sciences HN22C0173
52 Development of SHP2 allosteric inhibitor with dual mechanisms of targeting the RAS pathway and enhancing anti-tumor immunity
Small Molecules Nsclc, Colerectal Cancer, Head and Neck Cancer, Esophageal Cancer SHP2 Candidate KANAPH Therapeutics HN22C0066
53 Discovery of novel nucleic acid-sensing pathway modulators for the TNBC treatment
Small Molecules TNBC ENPP1 Hit Korea Institute of Science and Technology HN22C0063
54 Discovery of small molecular G9a inhibitor leads in advanced solid tumor: tumor growth inhibition and anti-cancer immunity activation
Small Molecules Solid Tumor G9a Lead Asan Medical Center HN22C0033
55 A small molecule inhibitor of the ubiquitin activating enzyme for regulating p53 in lung cancer
Small Molecules Lung cancer p53 or USE1 Lead Korea Research Institute of Chemical Technology HN21C1078
56 Non-clinical development of HM97662, an epigenetic protein EZH1/2 dual inhibitor, as a treatment for various cancers
Small Molecules Malignant tumor EZH1/2 Preclinical Hanmi Pharm. Co., Ltd. HN21C1077
57 Identification of Preclinical Small Molecule Candidate which induces STING protein expression by inhibiting TRIM29-mediated STING Ubiquitination
Small Molecules Solid Tumor TRIM29 Candidate SPARK Biopharma, Inc. HN21C1026
58 Pre-clinical Studies and IND Approval of First-in-class Cancer Stemness Blocking Anti-Cancer Agent, PMB212
Small Molecules Resistant cancer PIN1 Preclinical PimedBio HN21C0955
59 Development of HMGCLL1 inhibitory small molecule CML therapeutic anticancer drug
Small Molecules AML, CML HMGCLL1 Lead Samsung Medical Center HN21C0954
60 Discovery of lead compounds for the development of triple negative breast cancer treatments through HDAC6/8 dual inhibition
Small Molecules TNBC HDAC6/8 Lead Sookmyung Women’s University HN21C0952
61 Preclinical study of JPC-089, a blood cancer treatment targeting PIM kinase
Small Molecules AML PIM Kinase Preclinical Jeil Pharmaceutical CO.,LTD. HN21C0886
62 PhaseⅠclinical development of the 4th generation NSCLC-TKI BBT-176, which targets C797S-harboring EGFR mutations
Small Molecules NSCLC EGFR(C797S) Phase 1 Bridge Biotherapeutics, Inc. HN21C0859
63 Discovery of drug candidate for HER2 positive Breast cancer treatment using HER2 targeted Small molecule with high brain permeability
Small Molecules Breast cancer HER2 Candidate B2SBio Inc. HN21C0826
64 Novel Non-Covalent BTK Inhibitor, Exhibits Potent Anti-tumor Activity in B-Cell Lymphoma
Small Molecules CML BTK (C481S) Candidate Medytox HN21C0823
65 Non-clinical study of VRN08, an oral Mps1 inhibitor to modulate SAC for advanced solid tumor
Small Molecules TNBC and CDK4/6i resistant solid tumors Mps1 Preclinical Voronoi Inc. HN21C0580
66 Development of ***** Targeted New Drug Lead Compounds Activating IFN-γ for Immune Checkpoint Inhibitor Resistant Cancers
Small Molecules Cancer TPST2 Hit GIST(Gwangju Institute of Science & Technology) HN21C0196
67 Development of a lead compound targeting USP21 for inhibiting cancer metastasis
Small Molecules Colerectal cancer USP21 Lead Daegu Gyeongbuk Medical Innovation Foundation HN21C1210
68 Derivation of lead compound as TRIB2 inhibitor for development of triple negative breast cancer therapy
Small Molecules Breast cancer TRIB2 Lead GENESEN Co., Ltd. HN21C1201
69 Lead identification of GLS1 target via allosteric inhibition
Small Molecules Solid Tumor GLS1 Lead Korea Research Institute of Chemical Technology HN21C1180
70 Identification of next-generation EGFR degraders to treat Non-Small Cell Lung Cancer (NSCLC) patients
Small Molecules NSCLC EGFR mutation Lead Cyrus Therapeutics HN21C0965
BACK